Cinda anti-CD47/PD-L1 bispecific antibody Phase I clinical completion of China's first patient administration.

The study (CIBI322A101) was a phase Ia/Ib clinical study conducted in China to evaluate IBI322 treatment of subjects with advanced malignancies, with the main purpose of the study being to assess the safety, tolerance and antitumor activity of IBI322 bispecific antibody therapy in subjects with advanced malignancies with standard treatment failures.
IBI322 is an anti-CD47/PD-L1 bispecific antibody that blocks both PD-1/PD-L1 and CD47/SIRP-alpha pathways.
preclinical studies show that IBI322 can effectively block the binding of SIRP-alpha and CD47, induce macrophages to perform a phagocytopharycal effect on tumor cells expressing CD47, the ability is comparable to anti-CD47 monoantiphoresis;
also due to the presence of PD-L1, IBI322 selectivebinding to tumor cells is more capable than anti-CD47 monotophoid, thereby reducing the binding with CD47 on the surface of red blood cells, reducing the likelihood of associated toxicity.
, IBI322 has better anti-tumor activity and greater safety.
Note: The original text has a limitation.